Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm DogNeonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID
Jaguar Health Compliant with Nasdaq Bid Price RuleJAGX's securities continue to be listed and traded on Nasdaq
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing.
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock DividendCompany remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure ProgramReminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal failure diseases; click here to register
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of StockholdersLisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal DisordersCrofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS)
Jaguar Health Reports First Quarter 2026 FinancialsNet revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral CrofelemerFirst MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and no approved therapies, requiring lifelong parenteral support (PS)
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price RuleSAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (
NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel ("Panel") granting the Company's request for an extension to demonstrate compliance with the Nasdaq Listing Rules.
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy Designation
